Ge Wenhao, Zhou Dongkai, Zhu Lijun, Song Wei, Wang Weilin
Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310003, Zhejiang, China.
Division of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, China.
J Cancer. 2018 Dec 10;9(24):4783-4790. doi: 10.7150/jca.25908. eCollection 2018.
Everolimus, an oral mammalian target of rapamycin(mTOR) inhibitor, which acts upstream of the phosphoinositide 3-kinase/protein kinase B(PI3K/AKT) signaling pathway to downregulate cellular metabolism, growth, proliferation, and angiogenesis, has been shown to significantly prolong the progression-free survival of patients with advanced neuroendocrine tumors. Somatostatin analogues (SSAs) such as octreotide, lanreotide, and pasireotide, have been widely used for symptom control and antiproliferative effects in metastatic or unresectable neuroendocrine tumors. Both everolimus and SSAs have demonstrated antitumor effects in randomized controlled trials (RCTs) involving selected patients with neuroendocrine tumors, but the efficacy and safety of their combined use require further investigation. In this systematic review, we summarize the published studies that have investigated the use of everolimus and SSAs to provide a comprehensive understanding of their combined effects and better guidance for the treatment of neuroendocrine tumors.
依维莫司是一种口服的哺乳动物雷帕霉素靶蛋白（mTOR）抑制剂，作用于磷酸肌醇3激酶/蛋白激酶B（PI3K/AKT）信号通路的上游，以下调细胞代谢、生长、增殖和血管生成，已被证明可显著延长晚期神经内分泌肿瘤患者的无进展生存期。生长抑素类似物（SSA），如奥曲肽、兰瑞肽和帕瑞肽，已广泛用于转移性或不可切除神经内分泌肿瘤的症状控制和抗增殖作用。依维莫司和SSA在涉及特定神经内分泌肿瘤患者的随机对照试验（RCT）中均显示出抗肿瘤作用，但其联合使用的疗效和安全性需要进一步研究。在本系统评价中，我们总结了已发表的研究，这些研究探讨了依维莫司和SSA的使用情况，以全面了解它们的联合作用，并为神经内分泌肿瘤的治疗提供更好的指导。
